
==== Front
Acta Crystallogr E Crystallogr CommunActa Crystallogr E Crystallogr CommunActa Cryst. EActa Crystallographica Section E: Crystallographic Communications2056-9890International Union of Crystallography 25995874bg255210.1107/S2056989015007446ACSECIS2056989015007446Research CommunicationsCrystal structure of bis­[4-(1H-pyrrol-1-yl)phen­yl] ferrocene-1,1′-di­carboxyl­ate: a potential chemotherapeutic drug [Fe(C16H12NO2)2]Pérez Wanda I. aRheingold Arnold L. bMeléndez Enrique a*a University of Puerto Rico, Department of Chemistry, PO Box 9019, Mayaguez, Puerto Rico 00681, USAb University of California-San Diego, Department of Chemistry, Urey Hall 5128, 9500 Gilman Drive, La Jolla, CA 92093-0358, USACorrespondence e-mail: enrique.melendez@upr.edu01 5 2015 22 4 2015 22 4 2015 71 Pt 5 e150500536 539 02 4 2015 15 4 2015 © Pérez et al. 20152015This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.A full version of this article is available from Crystallography Journals Online.The solid-state structure of a disubstituted ferrocene with electrochemically active pendant groups has been determined. This is a potential chemotherapeutic drug.

The title iron(II) complex, [Fe(C16H12NO2)2], crystallizes in the ortho­rhom­bic space group Pbca with the Fe2+ cation positioned on an inversion center. The cyclo­penta­dienyl (Cp) rings adopt an anti conformation in contrast with other substituted ferrocenes in which the Cp rings appear in a nearly eclipsed conformation. The Cp and the aromatic rings are positioned out of the plane, with a twist angle of 70.20 (12)°, and the C(Cp)—C(CO) bond length is shorter than a typical C—C single bond, which suggests a partial double-bond character and delocalization with the Cp π system. The structure of the complex is compared to other functionalized ferrocenes synthesized in our laboratory.

crystal structuredisubstituted ferroceneanti­proliferativechemotherapeutic drugMCF-7pyrrole
==== Body
Chemical context   
The gold standard of treatment for breast cancer has traditionally been cisplatin, a metal-based agent. Its administration, alone or in combination with other drugs, is also highly effective against various other types of cancers, including ovarian, head and neck, bladder, testicular and lung cancers (Galanski et al., 2005 ▸; Sandler et al., 2011 ▸). However, its clinical use suffers from major drawbacks, such as severe toxic side effects including neurotoxicity, hepatotoxicity, and nephrotoxicity (Pabla & Dong, 2008 ▸), as well as a drug-resistance phenomenon which leads to unsuccessful treatment (Dempke et al., 2000 ▸). Consequently, other metal-based drugs have been investigated, among them ferrocenes (Köpf-Maier et al., 1984 ▸). Ferrocene has the versatility of easy functionalization providing a fertile field for structural modification and to study structure–activity relationship (SAR).

Our group has been working in this field for many years, leading to exciting and biologically active ferrocenes. A wide variety of pendant (functional) groups have been attached or linked to the Cp ring to tailor the anti-proliferative properties of ferrocene, many of them with great success (Braga & Silva, 2013 ▸; Gasser et al., 2011 ▸; Jaouen & Metzler-Nolte, 2010 ▸; Fouda et al., 2007 ▸; Jaouen, 2006 ▸; van Staveren & Metzler-Nolte, 2004 ▸; Nguyen et al., 2009 ▸; Top et al., 2003 ▸; Vessières et al., 2005 ▸, 2006 ▸; Meléndez, 2012 ▸; Vera et al., 2011 ▸, 2014 ▸). Lately, a new range of organic chemotherapeutic compounds have been studied using pyrrole derivatives. These pyrrole derivatives have revealed good anti-proliferative activity and an increase in membrane permeability, allowing the compounds to reach the nucleus (Ghorab et al., 2014 ▸; Abou El Ella et al., 2008 ▸; Chatzopoulou et al., 2014 ▸; Mohamed et al., 2013 ▸; Hassan et al., 2009 ▸; Esteves et al., 2010 ▸; Clark et al., 2007 ▸; Merighi et al., 2003 ▸). Therefore, we functionalized ferrocene with a pyrrole, 4-(1H-pyrrol-1-yl)phenol, obtaining three new ferrocenes: 1,1′-4-(1H-pyrrol-1-yl)phenyl ferrocenedi­carboxyl­ate, 1,4-(1H-pyrrol-1-yl)phenyl, 1′-carboxyl ferrocene­carboxyl­ate (Fc-(CO2-Ph-4-Py)CO2H) and 4-(1H-pyrrol-1-yl)phenyl ferro­cene­acetyl­ate (Fc-CH2CO2-Ph-4-Py). We investigated their biological activities on breast cancer cell line (MCF-7) and among these ferrocenes, 1,1′-4-(1H-pyrrol-1-yl)phenyl ferrocenedi­carboxyl­ate (I) was shown to be most active in this series (Pérez et al., 2015 ▸). Nevertheless, the solid-state structure of (I) has been elusive (Pérez et al., 2015 ▸). The importance of this complex is the incorporation of pyrrole groups, which are derivatives of biologically active compounds, as well as pyrrole being an electrochemically active group precursor of polymeric mat­erial. In addition, ferrocene anti­cancer activity has been associated with its redox behavior and the capability to produce reactive oxygen species (ROS) (Acevedo et al., 2012 ▸; Kovjazin et al., 2003 ▸; Tabbi et al., 2002 ▸; Osella et al., 2005 ▸). Thus, the attachment of an electrochemically active group on ferrocene could potentiate the production of ROS and enhance its anti­cancer activity.


Given that the solid-state structure of this complex is not available, we determined the crystal structure of bis­[4-(1H-pyrrol-1-yl)phen­yl] ferrocene-1,1′-di­carboxyl­ate, (I). Additionally, we compared the obtained crystal structure with other functionalized ferrocenes synthesized in our laboratory viz.: 4-bromo­phenyl (II) and 4-chloro­phenyl ferrocene­carboxyl­ate (III) (Vera et al., 2014 ▸), and 1,1′-methyl ferrocenedi­carboxyl­ate (IV) (Gao et al., 2009 ▸).

Structural commentary   
The asymmetric unit contains one half-mol­ecule since Fe2+ lies on an inversion center, Fig. 1 ▸. This symmetry is implied by the NMR data where only one set of signals were found for H2/H5 and H3/H4 of the Cp rings, as well as the H2/H6 and H3/H5 of the phenyl and H2/H5 and H3/H4 of the pyrrole groups. Consequently, the Cp rings adopt a perfect anti conformation. The average Fe—C(Cp) bond length is 2.044 (10) Å, which is very similar to that reported for ferrocene (Dunitz et al., 1956 ▸) and other structures previously reported by our lab (Vera et al., 2014 ▸; Gao et al., 2009 ▸). The Fe—C bond length of the substituted carbon [Fe—C1 2.032 (2) Å] is shorter that the remaining Fe—C bond lengths due to the inductive effect of the carboxyl­ate on the Cp ring. The twist angles between the Cp ring and the carboxyl­ate and the Cp ring and the aromatic ring are 14.4 (3)° (above the Cp plane) and 70.20 (12)°, respectively.

To put it in perspective, we compare (I) with previously synthesized ferrocenes in our group containing only one Cp functionalized and a phenyl group attached to the carboxyl­ate, but with Br and Cl instead of pyrrole in the 4-position, (II) and (III) (CCDC 949002 and 949003, Vera et al., 2014 ▸). First, in the 4-bromo­phenyl and 4-chloro­phenyl derivatives, the Cp rings are positioned in a nearly eclipsed conformation and parallel with stagger angles < 3° and Cp tilt angles of 0.48–1.25°. In contrast, (I) has a perfect anti conformation. The carbonyl carbon of (I) has a distorted trigonal–planar geometry, analogous to the 4-chloro­phenyl and 4-bromo­phenyl ferrocene­carboxyl­ates. The twist angles between the Cp ring and the carboxyl­ate for 4-bromo and 4-chloro­phenyl ferrocene­carboxyl­ates (6.75–10.15°) are smaller than that of the subject complex, 14.4 (3)°. Additionally, as mentioned previously, the carbonyl oxygen of (I) lies above the Cp plane whereas for the bromo and chloro derivatives, the carbonyl oxygens lie below the Cp plane. The twist angle between the Cp and the aromatic ring is 70.20 (12)° in (I), while in (II) and (III) the two rings are positioned at higher angles, approaching a perpendicular position.

The average Fe—C(Cp*) bond lengths of the substituted Cp rings in the 4-bromo and 4-chloro­phenyl derivatives are identical, within experimental error, as in (I) [2.044 (13) Å]. As mentioned before, the Fe—C bond length where the pendant group is attached is substanti­ally shorter than the remaining Fe—C(Cp) distances. The same bonding pattern is also observed for the 4-bromo and 4-chloro­phenyl ferrocene­carboxyl­ates. The C(Cp)—C(CO) bond length in (I), C1—C6, is shorter than a typical C—C single bond, [1.473 (3) versus 1.54 Å (single bond); Pauling, 1960 ▸]. This suggests partial double-bond character and delocalization with the Cp π system in analogous manner to that for the 4-bromo and 4-chloro derivatives.

In the structure of the disubstituted ferrocene Fe(C5H4CO2CH3)2, (IV) (Gao et al., 2009 ▸), the average Fe—C(Cp) bond lengths are 2.048 (11)/2.049 (14) Å, similar to the title complex but the Cp rings adopt almost an eclipsed conformation with a stagger angle of 2.37° (Fig. 2 ▸). In addition, the functional groups are not positioned perfectly anti to each other. The Fe—C(Cp)—C(CO) bond in (IV) [1.477 (4) Å] is notably shorter than a typical C—C single bond (1.54 Å), in a similar manner to the title complex, suggesting delocalization with the Cp π system.

Finally, (I) contains two π ring systems, 4-(1H-pyrrol-1-yl)phenyl, which in principle could be involved in intra­molecular π–π or C—H⋯π stacking similar to other 1,1′-disubstituted ferrocenes with an extended π ring system (Okabe et al., 2009 ▸; Togni et al., 1994 ▸; Gelin & Thummel, 1992 ▸). However, such π–π or C—H⋯π stacking is not observed in (I) since the Cp rings adopt an anti conformation.

Synthesis and crystallization   
The synthesis of (I) was accomplished by treating 1,1′-ferrocenedi­carb­oxy­lic acid with oxalyl chloride according to our recently published procedure (Pérez et al., 2015 ▸). 1H NMR (500 MHz, CDCl3) (δ p.p.m.): 7.37 (2H, d, ph; 3
J = 8.8 Hz), 7.25 (2H, d, py; 3
J = 2.8 Hz), 7.03 (2H, dd, ph; 3
J = 1.3 Hz), 6.34 (2H, dd, py; 3
J = 1.6 Hz), 5.08 (2H, overlapping doublets, AA′, Cp), 4.64 (2H, overlapping doublets, BB′, Cp). 13CNMR (125 MHz, CDCl3) (δ p.p.m.): 169.0 (C=O), 148.3, 138.6, 122.9, 121.5, 119.5, 110.5, 73.4, 72.4, 72.0. Analysis calculated for C32H24O4FeN2: C, 69.05; H, 4.40; found: C, 68.62; H, 4.46.

Crystallization of (I) was performed inside an NMR tube containing CD2Cl2 for a period of two weeks, obtaining block-shaped orange crystals suitable for X-ray diffraction.

Refinement   
Crystal data, data collection and structure refinement details are summarized in Table 1 ▸. H atoms were positioned in idealized locations (C(6)—H = 0.95, C(5)—H = 1.00 Å with U
iso(H) = 1.2U
eq(C).

Supplementary Material
Crystal structure: contains datablock(s) I. DOI: 10.1107/S2056989015007446/bg2552sup1.cif


 Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989015007446/bg2552Isup2.hkl


 CCDC reference: 1054149


 Additional supporting information:  crystallographic information; 3D view; checkCIF report


 EM is thankful for the financial support of NIH-RISE 2 Best program (NIH-R25GM088023) for the research assistantship of WIP (graduate student).

supplementary crystallographic 
information
Crystal data
[Fe(C16H12NO2)2]	Dx = 1.537 Mg m−3	
Mr = 556.38	Mo Kα radiation, λ = 0.71073 Å	
Orthorhombic, Pbca	Cell parameters from 2807 reflections	
a = 10.6386 (15) Å	θ = 2.7–28.1°	
b = 7.3948 (10) Å	µ = 0.67 mm−1	
c = 30.554 (4) Å	T = 100 K	
V = 2403.7 (6) Å3	Block, orange	
Z = 4	0.28 × 0.26 × 0.23 mm	
F(000) = 1152		
Data collection
Bruker APEXII CCD diffractometer	2247 reflections with I > 2σ(I)	
φ and ω scans	Rint = 0.077	
Absorption correction: multi-scan (SADABS; Bruker, 2010)	θmax = 28.4°, θmin = 2.7°	
Tmin = 0.833, Tmax = 0.877	h = −13→14	
12444 measured reflections	k = −9→9	
2999 independent reflections	l = −37→40	
Refinement
Refinement on F2	0 restraints	
Least-squares matrix: full	Hydrogen site location: inferred from neighbouring sites	
R[F2 > 2σ(F2)] = 0.044	H-atom parameters constrained	
wR(F2) = 0.117	w = 1/[σ2(Fo2) + (0.047P)2 + 0.928P] where P = (Fo2 + 2Fc2)/3	
S = 1.01	(Δ/σ)max < 0.001	
2999 reflections	Δρmax = 0.34 e Å−3	
178 parameters	Δρmin = −0.62 e Å−3	
Special details
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes)
are estimated using the full covariance matrix. The cell e.s.d.'s are taken
into account individually in the estimation of e.s.d.'s in distances, angles
and torsion angles; correlations between e.s.d.'s in cell parameters are only
used when they are defined by crystal symmetry. An approximate (isotropic)
treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s.
planes.	
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
	x	y	z	Uiso*/Ueq		
Fe1	0.5000	0.5000	0.5000	0.01323 (14)		
O1	0.23108 (15)	0.4748 (2)	0.41347 (5)	0.0213 (4)		
O2	0.41465 (13)	0.3430 (2)	0.39352 (4)	0.0173 (3)		
N1	0.37269 (16)	0.3889 (2)	0.21120 (5)	0.0133 (4)		
C1	0.3680 (2)	0.3523 (3)	0.46783 (7)	0.0149 (4)		
C2	0.3145 (2)	0.4294 (3)	0.50667 (6)	0.0169 (4)		
H2A	0.2415	0.5142	0.5081	0.020*		
C3	0.3857 (2)	0.3643 (3)	0.54286 (7)	0.0216 (5)		
H3A	0.3716	0.3970	0.5742	0.026*		
C4	0.4812 (2)	0.2469 (3)	0.52692 (7)	0.0191 (5)		
H4A	0.5454	0.1827	0.5451	0.023*		
C5	0.4712 (2)	0.2403 (3)	0.48035 (7)	0.0166 (4)		
H5A	0.5262	0.1693	0.4601	0.020*		
C6	0.3264 (2)	0.3975 (3)	0.42318 (6)	0.0144 (4)		
C7	0.3923 (2)	0.3684 (3)	0.34853 (6)	0.0145 (4)		
C8	0.48316 (19)	0.4601 (3)	0.32540 (7)	0.0155 (4)		
H8A	0.5502	0.5182	0.3404	0.019*		
C9	0.47630 (19)	0.4673 (3)	0.27993 (7)	0.0151 (4)		
H9A	0.5398	0.5288	0.2639	0.018*		
C10	0.37736 (19)	0.3853 (2)	0.25769 (6)	0.0121 (4)		
C11	0.28353 (19)	0.2994 (3)	0.28206 (7)	0.0149 (4)		
H11A	0.2137	0.2469	0.2674	0.018*		
C12	0.29095 (19)	0.2899 (3)	0.32731 (6)	0.0154 (4)		
H12A	0.2272	0.2302	0.3436	0.018*		
C13	0.2795 (2)	0.3154 (3)	0.18518 (7)	0.0174 (4)		
H13A	0.2077	0.2518	0.1954	0.021*		
C14	0.3076 (2)	0.3494 (3)	0.14240 (7)	0.0195 (5)		
H14A	0.2587	0.3153	0.1177	0.023*		
C15	0.4232 (2)	0.4449 (3)	0.14143 (7)	0.0213 (5)		
H15A	0.4661	0.4862	0.1161	0.026*		
C16	0.4613 (2)	0.4663 (3)	0.18374 (7)	0.0184 (4)		
H16A	0.5364	0.5248	0.1929	0.022*		
Atomic displacement parameters (Å2)
	U11	U22	U33	U12	U13	U23	
Fe1	0.0159 (2)	0.0111 (2)	0.0127 (2)	−0.00228 (16)	−0.00142 (16)	0.00108 (15)	
O1	0.0196 (9)	0.0274 (8)	0.0169 (8)	0.0076 (7)	−0.0004 (6)	−0.0006 (6)	
O2	0.0162 (8)	0.0220 (8)	0.0137 (7)	0.0029 (6)	−0.0003 (6)	−0.0013 (6)	
N1	0.0123 (8)	0.0123 (8)	0.0154 (8)	−0.0003 (7)	0.0015 (7)	−0.0003 (6)	
C1	0.0164 (10)	0.0125 (9)	0.0160 (10)	−0.0039 (8)	0.0003 (8)	−0.0003 (7)	
C2	0.0161 (10)	0.0168 (10)	0.0179 (10)	−0.0040 (9)	0.0031 (8)	0.0006 (8)	
C3	0.0292 (12)	0.0190 (11)	0.0165 (11)	−0.0081 (10)	0.0015 (9)	0.0016 (8)	
C4	0.0232 (12)	0.0139 (10)	0.0201 (11)	−0.0055 (9)	−0.0051 (9)	0.0046 (8)	
C5	0.0197 (11)	0.0105 (9)	0.0197 (11)	−0.0009 (9)	−0.0040 (9)	0.0007 (8)	
C6	0.0149 (10)	0.0121 (9)	0.0162 (10)	−0.0015 (8)	0.0004 (8)	−0.0014 (7)	
C7	0.0157 (10)	0.0137 (9)	0.0142 (10)	0.0024 (8)	−0.0008 (8)	−0.0014 (7)	
C8	0.0135 (10)	0.0150 (10)	0.0180 (10)	−0.0025 (8)	−0.0008 (8)	−0.0027 (8)	
C9	0.0127 (10)	0.0135 (9)	0.0192 (10)	−0.0006 (8)	0.0023 (8)	0.0003 (8)	
C10	0.0127 (10)	0.0085 (9)	0.0151 (10)	0.0031 (8)	0.0003 (8)	−0.0006 (7)	
C11	0.0118 (10)	0.0136 (9)	0.0193 (10)	−0.0027 (8)	−0.0012 (8)	0.0004 (8)	
C12	0.0150 (10)	0.0138 (9)	0.0173 (10)	−0.0010 (8)	0.0023 (8)	0.0018 (8)	
C13	0.0139 (10)	0.0163 (10)	0.0219 (11)	−0.0002 (9)	−0.0005 (8)	−0.0016 (8)	
C14	0.0211 (11)	0.0196 (11)	0.0177 (10)	0.0066 (9)	−0.0016 (9)	−0.0022 (8)	
C15	0.0250 (13)	0.0211 (11)	0.0179 (11)	0.0031 (10)	0.0048 (9)	0.0015 (9)	
C16	0.0161 (10)	0.0176 (10)	0.0217 (11)	−0.0032 (9)	0.0035 (9)	0.0024 (8)	
Geometric parameters (Å, º)
Fe1—C1	2.032 (2)	C3—H3A	1.0000	
Fe1—C1i	2.033 (2)	C4—C5	1.428 (3)	
Fe1—C5	2.035 (2)	C4—H4A	1.0000	
Fe1—C5i	2.035 (2)	C5—H5A	1.0000	
Fe1—C3i	2.050 (2)	C7—C8	1.376 (3)	
Fe1—C3	2.050 (2)	C7—C12	1.386 (3)	
Fe1—C2	2.051 (2)	C8—C9	1.392 (3)	
Fe1—C2i	2.051 (2)	C8—H8A	0.9500	
Fe1—C4i	2.055 (2)	C9—C10	1.392 (3)	
Fe1—C4	2.055 (2)	C9—H9A	0.9500	
O1—C6	1.201 (3)	C10—C11	1.398 (3)	
O2—C6	1.366 (2)	C11—C12	1.387 (3)	
O2—C7	1.407 (2)	C11—H11A	0.9500	
N1—C13	1.382 (3)	C12—H12A	0.9500	
N1—C16	1.386 (3)	C13—C14	1.364 (3)	
N1—C10	1.422 (3)	C13—H13A	0.9500	
C1—C5	1.427 (3)	C14—C15	1.418 (3)	
C1—C2	1.434 (3)	C14—H14A	0.9500	
C1—C6	1.473 (3)	C15—C16	1.364 (3)	
C2—C3	1.424 (3)	C15—H15A	0.9500	
C2—H2A	1.0000	C16—H16A	0.9500	
C3—C4	1.423 (3)			
				
C1—Fe1—C1i	180.0	C3—C2—Fe1	69.63 (13)	
C1—Fe1—C5	41.09 (8)	C1—C2—Fe1	68.75 (12)	
C1i—Fe1—C5	138.91 (8)	C3—C2—H2A	126.3	
C1—Fe1—C5i	138.91 (8)	C1—C2—H2A	126.3	
C1i—Fe1—C5i	41.09 (8)	Fe1—C2—H2A	126.3	
C5—Fe1—C5i	180.0	C4—C3—C2	108.66 (19)	
C1—Fe1—C3i	111.35 (8)	C4—C3—Fe1	69.90 (12)	
C1i—Fe1—C3i	68.66 (8)	C2—C3—Fe1	69.74 (12)	
C5—Fe1—C3i	111.27 (9)	C4—C3—H3A	125.7	
C5i—Fe1—C3i	68.73 (9)	C2—C3—H3A	125.7	
C1—Fe1—C3	68.65 (8)	Fe1—C3—H3A	125.7	
C1i—Fe1—C3	111.34 (8)	C3—C4—C5	107.97 (18)	
C5—Fe1—C3	68.73 (9)	C3—C4—Fe1	69.54 (12)	
C5i—Fe1—C3	111.27 (9)	C5—C4—Fe1	68.84 (11)	
C3i—Fe1—C3	180.0	C3—C4—H4A	126.0	
C1—Fe1—C2	41.11 (8)	C5—C4—H4A	126.0	
C1i—Fe1—C2	138.89 (8)	Fe1—C4—H4A	126.0	
C5—Fe1—C2	69.15 (9)	C1—C5—C4	107.75 (18)	
C5i—Fe1—C2	110.85 (9)	C1—C5—Fe1	69.36 (11)	
C3i—Fe1—C2	139.37 (9)	C4—C5—Fe1	70.30 (11)	
C3—Fe1—C2	40.63 (9)	C1—C5—H5A	126.1	
C1—Fe1—C2i	138.89 (8)	C4—C5—H5A	126.1	
C1i—Fe1—C2i	41.11 (8)	Fe1—C5—H5A	126.1	
C5—Fe1—C2i	110.85 (9)	O1—C6—O2	123.84 (18)	
C5i—Fe1—C2i	69.15 (9)	O1—C6—C1	126.17 (19)	
C3i—Fe1—C2i	40.63 (9)	O2—C6—C1	109.97 (18)	
C3—Fe1—C2i	139.37 (9)	C8—C7—C12	120.85 (19)	
C2—Fe1—C2i	180.0	C8—C7—O2	116.66 (18)	
C1—Fe1—C4i	111.29 (8)	C12—C7—O2	122.16 (18)	
C1i—Fe1—C4i	68.71 (8)	C7—C8—C9	119.63 (19)	
C5—Fe1—C4i	139.13 (9)	C7—C8—H8A	120.2	
C5i—Fe1—C4i	40.87 (9)	C9—C8—H8A	120.2	
C3i—Fe1—C4i	40.56 (9)	C10—C9—C8	120.67 (19)	
C3—Fe1—C4i	139.44 (9)	C10—C9—H9A	119.7	
C2—Fe1—C4i	111.44 (9)	C8—C9—H9A	119.7	
C2i—Fe1—C4i	68.56 (9)	C9—C10—C11	118.55 (18)	
C1—Fe1—C4	68.71 (8)	C9—C10—N1	120.40 (18)	
C1i—Fe1—C4	111.29 (8)	C11—C10—N1	121.05 (17)	
C5—Fe1—C4	40.87 (9)	C12—C11—C10	120.90 (19)	
C5i—Fe1—C4	139.13 (9)	C12—C11—H11A	119.5	
C3i—Fe1—C4	139.44 (9)	C10—C11—H11A	119.5	
C3—Fe1—C4	40.56 (9)	C7—C12—C11	119.31 (19)	
C2—Fe1—C4	68.56 (9)	C7—C12—H12A	120.3	
C2i—Fe1—C4	111.44 (9)	C11—C12—H12A	120.3	
C4i—Fe1—C4	180.00 (11)	C14—C13—N1	108.78 (19)	
C6—O2—C7	119.52 (16)	C14—C13—H13A	125.6	
C13—N1—C16	107.58 (17)	N1—C13—H13A	125.6	
C13—N1—C10	126.34 (17)	C13—C14—C15	107.54 (19)	
C16—N1—C10	126.08 (18)	C13—C14—H14A	126.2	
C5—C1—C2	108.28 (18)	C15—C14—H14A	126.2	
C5—C1—C6	127.65 (19)	C16—C15—C14	107.2 (2)	
C2—C1—C6	123.89 (19)	C16—C15—H15A	126.4	
C5—C1—Fe1	69.56 (12)	C14—C15—H15A	126.4	
C2—C1—Fe1	70.14 (12)	C15—C16—N1	108.9 (2)	
C6—C1—Fe1	122.25 (14)	C15—C16—H16A	125.6	
C3—C2—C1	107.3 (2)	N1—C16—H16A	125.6	
Symmetry code: (i) −x+1, −y+1, −z+1.

Figure 1 The mol­ecular structure of (I), with displacement ellipsoids drawn at the 30% probability level. Unlabelled atoms are related to labelled ones by the symmetry operation −x, −y, −z.

Figure 2 A Newman projection of Fe(C5H4CO2CH3)2.

Table 1 Experimental details
Crystal data	
Chemical formula	[Fe(C16H12NO2)2]	

M
r
	556.38	
Crystal system, space group	Orthorhombic, P
b
c
a
	
Temperature (K)	100	

a, b, c ()	10.6386(15), 7.3948(10), 30.554(4)	

V (3)	2403.7(6)	

Z
	4	
Radiation type	Mo K
	
 (mm1)	0.67	
Crystal size (mm)	0.28 0.26 0.23	
 	
Data collection	
Diffractometer	Bruker APEXII CCD	
Absorption correction	Multi-scan (SADABS; Bruker, 2010 ▸)	

T
min, T
max
	0.833, 0.877	
No. of measured, independent and observed [I > 2(I)] reflections	12444, 2999, 2247	

R
int
	0.077	
(sin /)max (1)	0.669	
 	
Refinement	

R[F
2 > 2(F
2)], wR(F
2), S
	0.044, 0.117, 1.02	
No. of reflections	2999	
No. of parameters	178	
H-atom treatment	H-atom parameters constrained	

max, min (e 3)	0.34, 0.62	
Computer programs: APEX2 and SAINT (Bruker, 2010 ▸), SHELXS97 and SHELXTL (Sheldrick, 2008 ▸) and SHELXL2013 (Sheldrick, 2015 ▸).
==== Refs
References
Abou El Ella, D. A., Ghorab, M. M., Noaman, E., Heiba, H. I. & Khalil, A. I. (2008). Bioorg. Med. Chem.
16, 2391–2402.
Acevedo, C. Y., Meléndez, E., Singh, S. P. & Ramirez-Vick, J. E. (2012). J. Cancer Sci. Ther.
4, 271–275.
Braga, S. S. & Silva, A. M. S. (2013). Organometallics, 32, 5626–5639.
Bruker (2010). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
Chatzopoulou, M., Patsilinakos, A., Vallianatou, T., Prnova, M. S., Žakelj, S., Ragno, R., Stefek, M., Kristl, A., Tsantili-Kakoulidou, A. & Demopoulos, V. J. (2014). Bioorg. Med. Chem.
22, 2194–2207.
Clark, M. P., George, K. M., Bookland, R. G., Chen, J., Laughlin, S. K., Thakur, K. D., Lee, W., Davis, J. R., Cabrera, E. J., Brugel, T. A., VanRens, J. C., Laufersweiler, M. J., Maier, J. A., Sabat, M. P., Golebiowski, A., Easwaran, V., Webster, M. E., De, B. & Zhang, G. (2007). Bioorg. Med. Chem. Lett.
17, 1250–1253.
Dempke, W., Voigt, W., Grothey, A., Hill, B. T. & Schmoll, H. J. (2000). Anticancer Drugs, 11, 225–236.
Dunitz, J. D., Orgel, L. E. & Rich, A. (1956). Acta Cryst.
9, 373–375.
Esteves, M. A., Ortet, O., Capelo, A., Supuran, C. T., Marques, S. M. & Santos, M. A. (2010). Bioorg. Med. Chem. Lett.
20, 3623–3627.
Fouda, M. F. R., Abd-Elzaher, M. M., Abdelsamaia, R. A. & Labib, A. A. (2007). Appl. Organomet. Chem.
21, 613–625.
Galanski, M., Jakupec, M. A. & Keppler, B. K. (2005). Curr. Med. Chem.
12, 2075–2094.
Gao, L. M., Hernández, R., Matta, J. & Meléndez, E. (2009). Metal Based Drugs, Article ID 420784, 10.1155/2009/420784.
Gasser, G., Ott, I. & Metzler-Nolte, N. (2011). J. Med. Chem.
54, 3–25.
Gelin, F. & Thummel, R. P. (1992). J. Org. Chem.
57, 3780–3783.
Ghorab, M. M., Alsaid, M. S., Ceruso, M., Nissan, Y. M. & Supuran, C. T. (2014). Bioorg. Med. Chem.
22, 3684–3695.
Hassan, S. M., El-Maghraby, A. A., Abdel Aal, M. M. & Bashandy, M. S. (2009). Phosphorus Sulfur Silicon, 184, 291–308.
Jaouen, G. (2006). Bioorganometallics, pp. 65–95. Weinheim: Wiley-VCH.
Jaouen, G. & Metzler-Nolte, N. (2010). Medicinal Organometallic Chemistry, pp. 81–117. Heidelberg, Dordrecht, London, New York: Springer-Verlag.
Köpf-Maier, P., Köpf, H. & Neuse, E. W. (1984). J. Cancer Res. Clin. Oncol
108, 336–340.
Kovjazin, R., Eldar, T., Patya, M., Vanichkin, A., Lander, H. M. & Novogrodsky, A. (2003). FASEB J.
17, 467–469.
Meléndez, E. (2012). Inorg. Chim. Acta, 393, 36–52.
Merighi, S., Mirandola, P., Varani, K., Gessi, S., Leung, E., Baraldi, P. G., Tabrizi, M. A. & Borea, P. A. A. (2003). Pharmacol. Ther.
100, 31–48.
Mohamed, M. S., Kamel, R. & Abd El-hameed, R. H. (2013). Med. Chem. Res.
22, 2244–2252.
Nguyen, A., Top, S., Pigeon, P., Vessières, A., Hillard, E. A., Plamont, M.-A., Huché, M., Rigamonti, C. & Jaouen, G. (2009). Chem. Eur. J.
15, 684–696.
Okabe, T., Nakazaki, K., Igaue, T., Nakamura, N., Donnio, B., Guillon, D. & Gallani, J.-L. (2009). J. Appl. Cryst.
42, 63–68.
Osella, D., Mahboobi, H., Colangelo, D., Cavigiolio, G., Vessières, A. & Jaouen, G. (2005). Inorg. Chim. Acta, 358, 1993–1998.
Pabla, N. & Dong, Z. (2008). Kidney Int.
73, 994–1007.
Pauling, L. (1960). The Nature of the Chemical Bond, 3rd ed. Ithaca: Cornell University Press.
Pérez, W. I., Soto, Y., Ortíz, C., Matta, J. & Meléndez, E. (2015). Bioorg. Med. Chem.
23, 471–479.
Sandler, A., Graham, C., Baggstrom, M., Herbst, R., Zergebel, C., Saito, K. & Jones, D. (2011). J. Thorac. Oncol.
6, 1400–1406.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112–122.
Sheldrick, G. M. (2015). Acta Cryst. C71, 3–8.
Staveren, D. R. van & Metzler-Nolte, N. (2004). Chem. Rev.
104, 5931–5986.
Tabbì, G., Cassino, C., Cavigiolio, G., Colangelo, D., Ghiglia, A., Viano, I. & Osella, D. (2002). J. Med. Chem.
45, 5786–5796.
Togni, A., Hobi, M., Rihs, G., Rist, G., Albinati, A., Zanello, P., Zech, D. & Keller, H. (1994). Organometallics, 13, 1224–1234.
Top, S., Vessières, A., Leclercq, G., Quivy, J., Tang, J., Vaissermann, J., Huché, & Jaouen, G. (2003). Chem. Eur. J.
9, 5223–5236.
Vera, J. L., Gao, L. M., Santana, A., Matta, J. & Meléndez, E. (2011). Dalton Trans.
40, 9557–9565.
Vera, J. L., Rullán, J., Santos, N., Jiménez, J., Rivera, J., Santana, A., Briggs, J., Rheingold, A. L., Matta, J. & Meléndez, E. (2014). J. Organomet. Chem.
749, 204–214.
Vessières, A., Top, S., Beck, W., Hillard, E. & Jaouen, G. (2006). Dalton Trans. pp. 529–541.
Vessières, A., Top, S., Pigeon, P., Hillard, E., Boubeker, L., Spera, D. & Jaouen, G. (2005). J. Med. Chem.
48, 3937–3940.
